Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment

• Published in: Journal of clinical oncology Vol. 41; no. 16_suppl; p. 8585
• Main Authors: Li, Xingya, Bi, Minghong, Su, Chunxia, Fang, Yong, WANG, Zibing, Yuan, Ying, Du, Xiuping, Lv, Tangfeng, Li, Yingyin
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2023

8585Background: AL8326 is a novel, orally administered, small molecule tyrosine kinase inhibitor (TKI). The primary objective of this Phase Ib/IIa study is to evaluate the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment. Methods: Patients...